Biofrontera's Ameluz® Hits Primary Endpoint in Phase 3 Trial for Actinic Keratosis
Event summary
- Biofrontera's Phase 3 trial for Ameluz® PDT met primary endpoint, showing 45.6% complete clearance vs. 16.7% for vehicle gel (p<0.0003).
- Study enrolled 172 patients with actinic keratosis on extremities, neck, and trunk.
- Company plans to submit sNDA to FDA in Q3 2026 for label expansion.
- Ameluz® demonstrated 73.1% lesion clearance and 86.3% patient satisfaction.
The big picture
Biofrontera's positive Phase 3 results position Ameluz® for potential label expansion into high-burden actinic keratosis fields beyond the face and scalp. This aligns with broader industry trends toward field-directed photodynamic therapies for sun-damaged skin. The strategic move could significantly increase Ameluz®'s market potential if regulatory approval is secured.
What we're watching
- Regulatory Pathway
- Whether FDA approval will expand Ameluz®'s addressable market beyond face and scalp treatments.
- Commercial Strategy
- How Biofrontera positions Ameluz® against existing actinic keratosis treatments post-approval.
- Clinical Expansion
- The pace at which Biofrontera advances trials for non-melanoma skin cancers and acne indications.
Related topics